Parkinson'
Conditions
Interventions
Drug
Duloxetine Duraion
SEP012014-AUG312016 Doseage
20mg/day or 40mg/day Times
one time per day P.O.
Sponsors
Department of Neurology, Juntendo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients are enrolled, who diagnosed clinically Parkinson's disease, complicated with depressive states, freezing gait, or chronic pain.
Exclusion criteria
Exclusion criteria: The patinets adopted exclusion criteria 1, succidal tendency, severe depression. 2, Severe renal or liver dysfunction 3, hypoersensitivity for duloxetine. 4, Taking MAO-B inhibitor 5, complicated cognitive decline; MMSE under 23. 6, Schisophrenia or bipolar disorder 7, Personality disorders 8, eleavated ESR or CRP in blood examination. 9, ANA over 320 times, or Rheumatoid factor over 100 IU/ml. 10, comorbidity of epilepsy or seizure 11, dysuremia, galucoma. 12, alchol abuser 13, attending dcotor judge not to iclude this protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FOG-Q:freezing of gait questionnair UPDRS:Unified Parkinson's Disease Rating Scale H & Y; Hoehn and Yahr stage HDR-S:Hamilton Depression Rating Scale Beck Score QIDS-J; Quick Inventory of Depressive Symptomatology HDS-R; revised Hasegawa's dementia scale MMSE; Mini-mental scale examination VAS; Visual Analog Scale FRS; Face rating scale WPI; Widespread pain index; from Fibromyalgia diagnostic criteria, ACR2010 | — |
Countries
Japan
Contacts
Public ContactKenya Nishioka
Department of Neurology, Juntendo University School of Medicine Department of Neurology
Outcome results
None listed